Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

61.29 +0.16 (+0.26%)
Streaming Delayed Price Updated: 12:03 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Globus Medical: Q4 Revenue Tops Forecast
Globus Medical's robust earnings for Q4 2024 were driven by strategic acquisitions and sustained innovation. 
Via The Motley Fool
Globus Medical’s (NYSE:GMED) Q4 Sales Beat Estimates
Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.6% year on year to $657.3 million. The company expects the full... 
Via StockStory
Topics Earnings
Globus Medical Reports Fourth Quarter and Full Year 2024 Results
From Globus Medical
Via GlobeNewswire
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Globus Medical (GMED) Q4 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
$100 Invested In Globus Medical 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Analyst Expectations For Globus Medical's Future
 
Via Benzinga
Top 2 Health Care Stocks That May Crash In February
 
Via Benzinga
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
Based on Fundamental Analysis it can be said that NYSE:GMED is a growth stock which is not overvalued. 
Via Chartmill
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
From Globus Medical
Via GlobeNewswire
Globus Medical Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
Why NYSE:GMED is Poised for High Growth.
A fundamental and technical analysis of (NYSE:GMED): Exploring GLOBUS MEDICAL INC - A (NYSE:GMED)'s high growth characteristics. 
Via Chartmill
Price Over Earnings Overview: Globus Medical
 
Via Benzinga
Why GLOBUS MEDICAL INC - A (NYSE:GMED) qualifies as a high growth stock.
Delving into GLOBUS MEDICAL INC - A (NYSE:GMED)'s high Growth Prospects. 
Via Chartmill
16 Analysts Have This To Say About Globus Medical
 
Via Benzinga
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
From Globus Medical
Via GlobeNewswire
The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Inspire Medical's Sleep Innovations Driving Big Gains
Inspire Medical, which makes innovative apnea relief devices, hit a key performance benchmark as its Relative Strength Rating jumped to 81. 
Via Investor's Business Daily
Should you consider GLOBUS MEDICAL INC - A (NYSE:GMED) for high growth investing?
Unlocking the high Growth Potential of GLOBUS MEDICAL INC - A (NYSE:GMED). 
Via Chartmill
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Evaluating Globus Medical: Insights From 11 Financial Analysts
 
Via Benzinga
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
Globus Medical Launches ExcelsiusHub™ Navigation System
From Globus Medical
Via GlobeNewswire
What 7 Analyst Ratings Have To Say About Globus Medical
 
Via Benzinga
Despite its growth, NYSE:GMED remains within the realm of affordability.
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
CVS Health, Johnson Controls And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.